Your shopping cart is currently empty

Pentixather is a radiolabeled peptide that targets CXCR4. By disrupting the interaction between leukemia cells and the bone marrow microenvironment through targeting the CXCR4/CXCL12 signaling axis, Pentixather reduces the retention of leukemia cells in protective bone marrow niches, thereby increasing their sensitivity to treatment. It is applicable in studies related to acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Pentixather is a radiolabeled peptide that targets CXCR4. By disrupting the interaction between leukemia cells and the bone marrow microenvironment through targeting the CXCR4/CXCL12 signaling axis, Pentixather reduces the retention of leukemia cells in protective bone marrow niches, thereby increasing their sensitivity to treatment. It is applicable in studies related to acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). |
| Molecular Weight | 701.83 |
| Formula | C36H47N9O6 |
| Cas No. | 1339959-27-1 |
| Smiles | C(C1=CC2=C(C=C1)C=CC=C2)[C@@H]3NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCN)N(C)C(=O)[C@@H](CC4=CC=C(O)C=C4)NC(=O)CNC3=O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.